HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients
[vc_row][vc_column][vc_custom_heading text="HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_r ...
Madrigal Pharmaceuticals’ Resmetirom Receives FDA Breakthrough Therapy Designation for NASH Treatment with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA's) Breakthrough therapy designation for resmetirom in the treatment of NASH patients with liver fibrosis. The company ...
Candel Therapeutics Receives U.S. FDA Fast Track Designation for CAN-2409 to Treat Stage III/IV NSCLC Patients
Candel Therapeutics receives FDA's fast track designation for CAN-2409, a viral immunotherapy developed to improve survival in combination with valacyclovir and pembrolizumab to treat stage III/IV non ...
SAB Biotherapeutics’ SAB-176 Granted Breakthrough Therapy Designation by FDA for High-Risk Patients with Type A and B Influenza
SAB Biotherapeutics receives the FDA's Breakthrough Therapy Designation for SAB-176, an investigational therapeutic for post-exposure prophylaxis of Type A and Type B influenza illness in high-risk pa ...
Regenxbio’s RGX-202 Gene Therapy for Duchenne Muscular Dystrophy Receives Fast Track Designation from FDA
Regenxbio Inc. has received a fast track designation from the FDA for its innovative gene therapy, RGX-202, aimed at treating Duchenne muscular dystrophy. This therapy has been designed to deliver and ...
Glaucoma Facts & Statistics
[vc_row][vc_column][vc_custom_heading text="Glaucoma Facts & Statistics" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc_column css=".vc_custom_166 ...
Sumitomo Pharma’s TP-1287 granted FDA Orphan Drug and Rare Pediatric Disease Designations for Ewing sarcoma
Sumitomo Pharma Oncology, Inc. has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for TP-1287, an oral CDK9 inhibitor that is being investigated for the treatment of ...
Verismo Therapeutics Receives Fast Track Designation from FDA for SynKIR-110, a Novel CAR T Therapy for Mesothelioma Treatment
Verismo Therapeutics, a clinical-stage company specializing in CAR T technology, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative drug, SynKIR-11 ...
Number of People with Dementia in High, Middle and Low Income Countries
[vc_row][vc_column][vc_custom_heading text="Number of People with Dementia in High, Middle and Low Income Countries" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_ro ...
Abbisko Cayman’s ABSK012 Granted FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment
Abbisko Therapeutics, a subsidiary of Abbisko Cayman, has been awarded an orphan drug designation by the US Food and Drug Administration (FDA) for ABSK012, an FGFR4 mutant inhibitor that treats soft t ...